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Summary
The general transcription factor TFIIB plays a central role in
preinitiation complex (PIC) assembly and the recruitment of
RNA polymerase II (RNA pol II) to the promoter [1]. Recent
studies have revealed that TFIIB engages in contact with
the transcription termination region and also with com-
plexes that are involved in 30 end processing and/or termina-
tion [2–9]. Here we report that TFIIB can be phosphorylated
within the N terminus at serine 65 in vivo and that the phos-
phorylated form of TFIIB is present within (PICs). Surpris-
ingly, TFIIB serine 65 phosphorylation is required after the
phosphorylation of serine 5 of RNA pol II C-terminal domain
(CTD) has occurred, but before productive transcription initi-
ation begins. We show that phosphorylation of TFIIB at
serine 65 regulates the interaction between TFIIB and the
CstF-64 component of the CstF 30 cleavage and polyadenyla-
tion complex. This directs the recruitment of CstF (cleavage
stimulatory factor) to the terminator and also the recruitment
of the CstF and CPSF (cleavage and polyadenylation specific
factor) complexes to the promoter. Our results reveal that
phosphorylation of TFIIB is a critical event in transcription
that links the gene promoter and terminator and triggers
initiation by RNA pol II.
Results and Discussion
Phosphorylation of TFIIB In Vitro
We tested whether human TFIIB could be phosphorylated
when incubated with a crude HeLa cell nuclear extract. GST,
GST-TFIIB (GST-IIB), GST-IIBN (residues 1–124), and GST-
IIBC (residues 124–316) were expressed in E. coli and purified
by binding to glutathione agarose beads. The GST fusion
proteins, linked to beads, were incubated with HeLa nuclear
extract in the presence of [g-32P]ATP. The beads were washed
extensively, and proteins were released by heating to 95C in
SDS-PAGE loading dye, resolved by SDS-PAGE followed by
staining with Coomassie blue, and then subjected to autoradi-
ography. Figure 1A shows the autoradiogram (above) and the
same Coomassie-stained gel (below). The GST-IIB fusion
protein, but not GST, incorporated the radiolabeled phos-
phate. Analysis of the GST-IIBN and GST-IIBC derivatives
demonstrated that the radiolabel was exclusively incorporated
into the N-terminal 124 residues of TFIIB, and not into the
C-terminal core domain.*Correspondence: sr237@buffalo.edu
3Present Address: Beatson Institute for Cancer Research, Garscube Estate,
Glasgow G61 1BD, UKDNA-PK has previously been reported to phosphorylate
TFIIB residue serine 65 in vitro [10]. We therefore produced
a GST-TFIIB (1–124) derivative in which serine 65 had been
substituted with alanine (S65A). GST, GST-IIBN, and GST-
IIBN S65A were incubated with the 0.1, 0.3, 0.5, and 1.0 M
salt fractions derived from phosphocellulose chromatography
of HeLa nuclear extract (Figure 1B). The TFIIB kinase activity
present in the 0.5 M P11 fraction (which contains the major
TFIIB kinase activity) and the 1.0 M P11 fraction showed a
significant reduction in kinase activity toward the TFIIB S65A
derivative when compared with wild-type TFIIB, suggesting
that serine 65 might be a major site of the phosphorylation.
TFIIB Serine 65 Is Required for Transcription In Vivo
We used transient transfection of human embryonic kidney
293T (HEK293T) cells to analyze the effect of ectopic expres-
sion of a TFIIB S65A mutant derivative on the activity of a
luciferase reporter plasmid linked to the adenovirus major
late (AdML) core promoter under the control of the activator
BxGalII. Expression of wild-type TFIIB did not significantly
affect transcription of the reporter. As we have reported previ-
ously, the mutant TFIIB derivative R66E inhibited transcription
([11, 12]; Figure 1C). Similarly, the TFIIB S65A mutant deriva-
tive inhibited transcription. Immunoblotting with anti-T7 anti-
bodies (to detect an epitope tag at the C terminus of the
ectopically expressed TFIIB) confirmed the equivalent expres-
sion of the TFIIB derivatives.
We next employed an RNA interference (RNAi)-based
approach described by us previously to analyze the function
(or functions) of the TFIIB mutant derivatives in living cells in
the absence of endogenous TFIIB [12]. Vector-derived RNAi
was used to ablate the expression of endogenous TFIIB while,
simultaneously, wild-type TFIIB or TFIIB S65A that contains
a silent mutation within the RNAi target sequence was intro-
duced. Immunoblotting with anti-TFIIB antibodies confirmed
the RNAi-mediated knockdown of TFIIB and equivalent
expression of wild-type TFIIB and TFIIB S65A (Figure 1D).
The expression of wild-type TFIIB restored reporter activity
but, consistent with its inhibitory activity, expression of TFIIB
S65A did not.
Next, we tested the effect of ectopic expression of the
potential phosphomimetic TFIIB mutant derivative S65E on
transcription of the AdML reporter. As before, expression of
TFIIB S65A was a potent inhibitor of AdML reporter activity
(Figure 1E). However, expression of the TFIIB S65E mutant
derivative elicited an effect similar to that observed with
wild-type TFIIB, suggesting that TFIIB S65E is a phosphomi-
metic protein that can support transcription.
We next analyzed a selection of endogenous genes to deter-
mine whether their activity was affected by the expression of
the TFIIB derivatives. Plasmids driving expression of wild-
type TFIIB or the mutant TFIIB derivatives were transfected
into 293T cells along with a plasmid driving expression of
green fluorescent protein (GFP). Forty-eight hours later, the
transfected cells were separated and collected by fluores-
cence-activated cell sorting (FACS), and the expression levels
of b-tubulin, GAPDH, g-actin, and amphiregulin were analyzed
by quantitative polymerase chain reaction, normalized against
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Figure 1. Phosphorylation of TFIIB Serine 65 In Vitro and the Effects of
Serine 65 Substitutions on Transcription In Vivo
(A) One microgram each of recombinant GST, GST-IIB, or derivatives GST-
IIBN (residues 1–124) or GST-IIBC (residues 124–316) linked to glutathione
agarose beads prepared as described previously [26] were incubated with
[g-32P]ATP and crude HeLa cell nuclear extract. Following the kinase reac-
tion, the beads were washed and separated by SDS-PAGE, the gel was
stained with Coomassie blue and dried, and 32P incorporation was then visu-
alized by autoradiography. GST-IIB, GST-IIBC, GST-IIBN, and GST are indi-
cated at right. The truncation product of the GST-IIB fusion protein, which
likely contains the N terminus of TFIIB, also incorporated the radiolabel.
(B) HeLa cell nuclear extract was subject to P11 chromatography, with step
elution at 0.1, 0.3, 0.5, and 1.0 M KCl. The fractions (labeled above the lanes)
were incubated with recombinant GST, GST-IIBN, or GST-IIBN S65A in the
presence of [g32P]ATP and analyzed as in (A).
(C) HEK293T cells were transfected with 1 mg of AdML luciferase reporter
(which contains five GAL4 DNA-binding sites), 1 mg of plasmid driving expres-
sion of BxGalII (GAL4 residues 1–147 linked to the region II activation domain
of GAL4), and 500ngofvector drivingexpression ofT7-tagged wild-typeTFIIB
or the mutant derivatives R66E and S65A. Forty-eight hours later, cell lysates
were prepared and luciferase activity was measured, or western blotting with
anti-T7 and b-tubulin antibodies was performed (below). Data are representa-
tive of at least three independent experiments performed in triplicate.
(D) Cells were transfected with 1 mg pSUPER RNAi and 500 ng of vector
driving expression of the indicated TFIIB derivatives and analyzed as in
(C), except that anti-TFIIB antibodies were used in the immunoblot.
(E) As in (C), except that TFIIB mutant derivative S65E was also included in
the assay, HA-tagged TFIIB derivatives were employed, and anti-HA anti-
bodies were used in the immunoblot.
(F) HEK293T cells were transfected with vector driving expression of wild-
type TFIIB or the indicated TFIIB mutant derivatives along with a vector
driving expression of GFP. The transfected cells were selected by fluores-
cence-activated cell sorting (FACS) after 48 hr, and total RNA was extracted.
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)
was performed to detect b-tubulin, GAPDH, g-actin, and amphiregulin
mRNA levels relative to the polymerase I (pol I) 18S transcript.
Error bars denote standard deviation (SD).
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549the RNA polymerase I (pol I) 18S transcript (Figure 1F). Expres-
sion of TFIIB S65A or TFIIB R66E resulted in the inhibition of all
of the pol II transcripts that we tested, but the phosphomimetic
TFIIB S65E did not.
The TFIIB Mutant Derivatives Are Defective at One or More
Events following Preinitiation Complex Assembly
Chromatin immunoprecipitation (ChIP) was employed to
analyze the effect of TFIIB serine 65 substitution on the
assembly of TFIIB at the g-actin promoter in vivo. Empty
expression vector or vector driving expression of T7 epitope-
tagged wild-type TFIIB or the derivatives was transfected
into 293T cells, and 48 hr later, ChIP was performed with either
anti-T7 tag antibodies or control mouse IgG antibodies. The
promoter region of the g-actin gene and also a control nonpro-
moter region were amplified, and the data were expressed as
fold enrichment of the g-actin promoter relative to the nonpro-
moter region (Figure 2A). The results show that TFIIB S65A,
S65E, and R66E were recruited to the g-actin promoter to
a level similar to that observed with wild-type TFIIB.
We next analyzed the effect of the TFIIB mutant derivatives
on the recruitment of TFIIF to the g-actin promoter. To ensure
that TFIIF recruitment was only analyzed in transfected cells,
along with the TFIIB expression plasmids we cotransfected
a plasmid driving expression of a HA-tagged RAP74 subunit
of the TFIIF complex. Expression of the HA-tagged RAP74
was confirmed by immunoblotting whole-cell extracts with
anti-HA antibodies (see Figure S1A available online). ChIP
was performed with either anti-HA antibodies or a control
antibody, and the data are presented as fold enrichment of
the g-actin promoter relative to the pol I-transcribed 18S
gene (Figure 2A, second panel from top). HA-tagged RAP74
was recruited to the g-actin promoter in the presence of all
of the transfected TFIIB derivatives.
We next tested whether TFIIB serine 65 is important for pol II
recruitment to promoters, using the GFP/FACS protocol
described above to harvest only the transfected cells. ChIP
was performed with anti-pol II C-terminal domain (CTD) anti-
body or a control antibody. As observed with TFIIF, pol II
was also recruited to the g-actin promoter when the cells
were transfected with wild-type TFIIB or the TFIIB mutant
derivatives (Figure 2A). Using the same approach, we deter-
mined that both TFIIE (b subunit) and TFIIH (CDK7) were also
recruited to the g-actin promoter in the presence of all of the
TFIIB mutant derivatives (Figure 2A). Comparable data were
obtained when we analyzed the b-tubulin and GAPDH
promoters (Figures S1A and S2A). Thus, TFIIB S65A and also
TFIIB R66E manifest their transcriptional defects at an event
following preinitiation complex (PIC) assembly.
We next performed ChIP analysis to examine the presence
of pol II within the coding region of the g-actin gene. Cells
were transfected as above, and ChIP was performed with
anti-pol II CTD antibodies. Primers were used to amplify two
internal regions of the g-actin gene (Figure 2B, left; primer
locations are shown in schematic above). Pol II was readily
detected within the coding region of the g-actin gene when
either wild-type TFIIB or TFIIB S65E was expressed. In
contrast, and consistent with the transcription data, we were
unable to detect pol II within the coding region when TFIIB
S65A or TFIIB R66E was expressed. Translocation of TFIIF
(as HA-tagged RAP74) into the g-actin gene internal region
was also blocked by expression of either TFIIB S65A or
R66E (Figure 2B, right). Thus, TFIIB S65A and R66E can form
PICs that contain pol II, TFIIF, TFIIE, and TFIIH but fail to
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Figure 2. TFIIB B Finger/B Reader Mutant Deriv-
atives Are Able to Support Preinitiation Complex
Assembly but Are Defective in Supporting the
Transition of Pol II to a Productive Transcription
Complex
(A) Left: HEK293T cells were transfected with
pcDNA3 vector, pcDNA3 driving expression of
T7-tagged wild-type TFIIB, or the mutant deriva-
tives indicated. Vector driving expression of
HA-tagged RAP74 was cotransfected into the
cells where indicated. For endogenous pol II,
TFIIE, and TFIIH analysis, cells were cotrans-
fected with a plasmid driving GFP and processed
as described in the text. Chromatin immunopre-
cipitation (ChIP) was performed as described
previously [27] with modifications (see Supple-
mental Experimental Procedures) with the anti-
bodies indicated, and data are presented as
fold enrichment of g-actin promoter DNA over
nonpromoter DNA of the same gene or the pol
I-transcribed 18S gene in the immunoprecipita-
tion. Right: schematic diagram of the g-actin
gene showing the TATA box/promoter region,
open reading frames (boxes), and terminator
(vertical lines). The positions of real-time PCR
products used in the ChIP analysis are marked
relative to the transcription start site.
(B) ChIP analysis was performed with anti-pol II
C-terminal domain (CTD) (left) or anti-HA (TFIIF,
RAP74; right) antibody, and PCR analysis of
immunoprecipitated chromatin was performed
on coding regions 1 and 2 of the g-actin gene.
(C) ChIP of phosphorylated CTD at serine 5
(CTDp5) was performed as in (B), except that
S5-P-CTD antibody was used in the immunopre-
cipitation.
Error bars denote SD. See also Figures S1 and S2.
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550form a productive transcription complex. Comparable effects
were observed when we analyzed the b-tubulin and GAPDH
genes (Figures S1B and S2B).
The Integrity of TFIIB Serine 65 Is Required after Pol II CTD
Serine 5 Phosphorylation
At transcription initiation, the pol II CTD is phosphorylated at
serine 5 [13]. We therefore determined whether the TFIIB
mutant derivatives support phosphorylation of serine 5 of the
pol II CTD. Cells were transfected as above, and ChIP was per-
formed with anti-phosphoserine 5 CTD antibodies (CTDp5).
Primers were used to amplify four distinct regions across the
g-actin gene from the promoter to the termination region
(Figure 2C). Expression of either wild-type TFIIB or TFIIB
S65E supported phosphorylation of pol II CTD serine 5 at the
promoter and within the early coding region of the g-actin
gene but then declined toward the 30 region of the gene. These
results are consistent with the known function of pol II CTD
serine 5 phosphorylation mainly at, or proximal to, the
promoter [13]. However, when we analyzed the TFIIB S65A
and R66E mutant derivatives, we surprisingly found that they
elicited distinct effects on pol II CTD serine 5 phosphorylation.
The expression of TFIIB R66E caused a significant reduction in
the detection of pol II serine 5 phosphorylation at the promoter
and also the early coding region of the g-actin gene, suggest-
ing that the assembly of PICs containing TFIIB R66E prevents
the phosphorylation of pol II CTD serine 5 even though TFIIH is
present within the complex (see bottom panel of Figure 2A).
The mechanistic basis for this effect is not clear, but it is
possible that either TFIIH or pol II are incorrectly aligned withinthe PIC or that TFIIB can directly modulate the activity of TFIIH
or perhaps other components of the PIC that augment CDK7
activity [14].
In contrast to the effect elicited by TFIIB R66E, expression of
TFIIB S65A did not prevent the phosphorylation of pol II serine
5 at the promoter but significantly reduced its occupancy
at the early coding region of the g-actin gene. Comparable
results were obtained when we examined the b-tubulin
and GAPDH genes (Figures S1C and S2C). Thus, the TFIIB
mutant derivatives R66E and S65A manifest their defects in
supporting transcription at distinct events in the transcription
sequence. PICs that form with TFIIB R66E are rendered defec-
tive prior to pol II CTD serine 5 phosphorylation. In contrast,
complexes that contain TFIIB S65A undergo phosphorylation
of pol II CTD serine 5, but the complexes are not transcription-
ally productive.
TFIIB Is Phosphorylated at Serine 65 In Vivo
We generated and purified antibodies against a TFIIB peptide
containing phosphorylated serine 65 and then used immuno-
blotting to test their specificity. GST, GST-IIBN, and GST-IIBN
S65A linked to glutathione agarose beads were incubated
with the 0.5 M fraction derived from fractionation of HeLa
cell nuclear extract over a P11 column (as in Figure 1), or
with buffer alone, in an in vitro kinase assay. Immunoblotting
was then performed with either anti-TFIIB antibodies or with
the purified antibodies raised against phosphoserine 65
(pS65-TFIIB; Figure 3A). The pS65-TFIIB antibody produced
a robust signal against GST-IIBN, but not with the S65A mutant
derivative, which only occurred when the fusion proteins had
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Figure 3. Phosphorylation of TFIIB at Serine 65 In Vivo and Localization
at the Promoter
(A) GST or the indicated GST-TFIIB derivatives were incubated with either
150 mM KCl-buffer D or the same buffer containing 0.5 M P11 fraction (as
described in Figure 1). The kinase reaction was terminated by the addition
of SDS buffer, and the samples were subjected to SDS-PAGE. Western blots
were performed with either anti-pS65-TFIIB antibody or anti-TFIIB antibody.
(B) Endogenous TFIIB was immunoprecipitated from HEK293T whole-cell
extracts with anti-TFIIB antibodies. Phosphatase inhibitors were used
where indicated (+) in the lysis and wash buffers. The immunoprecipitates
were analyzed as in (A). Quantitation of select bands is shown below the
autoradiogram.
(C) Immunoprecipitation of endogenous TFIIB was performed in lysis buffer
containing phosphatase inhibitors. After the final wash, the antibody-
antigen complex was treated with lambda phosphatase (l-pptase) where
indicated (+) and then subjected to SDS-PAGE and blotting as in (A).
(D) U2OS cells were separated into cytoplasmic and nuclear fractions. The
fractions were then incubated with or without lambda phosphatase as indi-
cated and subjected to SDS-PAGE. Western blots were performed with anti-
TFIIB, anti-b-tubulin, or anti-pS65-TFIIB antibodies.
(E) Sonicated chromatin was prepared from 293T cells and incubated with
lambda phosphatase where indicated. ChIP was performed with general
anti-TFIIB antisera, anti-pS65-TFIIB antibodies, or control antibodies. The
data are presented as fold enrichment of g-actin, b-tubulin, and GAPDH
promoter DNA over nonpromoter DNA in the immunoprecipitation. Error
bars denote SD.
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551been incubated with the 0.5 M P11 fraction and not with buffer
alone. Blotting the same samples with general TFIIB antisera
produced a signal with both wild-type TFIIB and the S65A
derivative that was not dependent on prior incubation of the
fusion protein with the 0.5 M P11 fraction. Thus, the pS65-
TFIIB antibodies react specifically with TFIIB only when phos-
phorylated at serine 65.
We next prepared cell lysates from 293T cells in the pres-
ence or absence of phosphatase inhibitors, immunoprecipi-
tated the endogenous TFIIB, and then immunoblotted witheither the pS65-TFIIB antibody or general anti-TFIIB anti-
body (Figure 3B). Immunoblotting with the general TFIIB anti-
body demonstrated equivalent immunoprecipitation of TFIIB
regardless of the presence or absence of phosphatase inhibi-
tors during the lysate preparation (quantitation is shown below
the autoradiogram). In contrast, immunoblotting the same
samples with the pS65-TFIIB antibody showed a significantly
lower signal in the TFIIB immunoprecipitate derived from
the preparation that lacked phosphatase inhibitors. Next, we
prepared TFIIB immunoprecipitates as above and incubated
the samples with lambda phosphatase (l-pptase). This treat-
ment did not affect the total TFIIB protein level but significantly
reduced the signal with the anti-pS65-TFIIB antibodies
(Figure 3C). Thus, the recognition of TFIIB by anti-pS65-TFIIB
antibody is dependent on TFIIB phosphorylation in vivo.
We also used the anti-pS65-TFIIB antibodies to immunoblot
nuclear and cytoplasmic extracts prepared in the presence of
phosphatase inhibitors from U2OS cells. The extracts were
incubated in the absence or presence of lambda phosphatase
and then immunoblotted as before (Figure 3D). As expected,
endogenous TFIIB was present exclusively in the nuclear frac-
tion and b-tubulin in the cytoplasmic fraction. Immunoblotting
with pS65-TFIIB antibody revealed a significant reduction in
signal when the samples had been incubated with lambda
phosphatase. Collectively, the data in Figures 3A–3D suggest
that a portion of endogenous TFIIB in 293T cells and U2OS
cells is phosphorylated at serine 65.
Next, we used ChIP to determine whether TFIIB phosphory-
lated at serine 65 is present within PICs. Following the frag-
mentation of chromatin derived from nontransfected 293T
cells and prior to the addition of antibodies, the samples
were incubated with buffer alone or with buffer containing
lambda phosphatase. ChIP was then performed with control
antibodies, general anti-TFIIB antibodies, or anti-pS65-TFIIB
antibodies. The g-actin, b-tubulin, and GAPDH promoters
were then amplified, and the data are presented graphically
as fold enrichment over the signal generated by amplification
of a control internal region of each gene (Figure 3E). The
ChIP signal generated by the general TFIIB antibodies was
not affected by the treatment of the chromatin with lambda
phosphatase. In contrast, ChIP of the three promoters by the
anti-pS65 IIB antibodies was significantly reduced when the
chromatin samples had been incubated with lambda phospha-
tase. Taken together, the data in Figure 3 suggest that a portion
of TFIIB is phosphorylated at serine 65 in vivo and that this
includes promoter-bound TFIIB.
Phosphorylation of TFIIB Serine 65 Is Required for the
Recruitment of 30 Termination Complexes to the Promoter
and Terminator
Our data so far suggest that phosphorylation of TFIIB serine 65
is important for one or more steps that occur after the phos-
phorylation of serine 5 of the pol II CTD. TFIIB has been linked
with the CPSF (cleavage and polyadenylation specific factor)
and CstF (cleavage stimulatory factor) complexes, which are
recruited to the PIC and are required for cleavage and polyade-
nylation of mRNA [3, 4]. We therefore used ChIP to determine
whether the recruitment of Ssu72 (a component of the CPSF
complex) and CstF-64 (a component of the CstF complex)
to the promoter or terminator was dependent on the integrity
of TFIIB residue serine 65. 293T cells were transfected as
above and then subjected to FACS, and ChIP was performed
with anti-Ssu72 antibodies, anti-CstF-64 antibodies, or control
antibodies. The promoter and terminator regions of the
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Figure 4. Recruitment of mRNA Processing
Factors to the Promoter and Terminator Is Regu-
lated by the Phosphorylation of TFIIB Residue
Serine 65
(A) HEK293T cells were transfected with pcDNA3
vector, the same vector driving expression of
wild-type TFIIB or TFIIB S65A, and vector driving
expression of GFP. FACS sorting was used
to select the transfected cells. ChIP analysis
was performed with anti-Ssu72 antibody, anti-
CstF-64 antibody, or control rabbit IgG. qPCR
was performed, and data are presented as
fold enrichment of specific b-tubulin, g-actin, or
GAPDH promoter DNA (left) or terminator (primer
R-3, right) over the pol I-transcribed gene 18S
DNA. Error bars denote SD.
(B) HEK293T whole-cell extract was prepared in
the presence of phosphatase inhibitors and
then treated with lambda phosphatase where
indicated. The cell lysates were then subjected
to immunoprecipitation with control antibodies
or anti-TFIIB, anti-Ssu72, or anti-CstF-64 anti-
bodies. Immunoprecipitates (top) and samples
of the input lysates (bottom) were immunoblotted
with anti-TFIIB antibody.
(C) Top: HEK293T cells were transfected with
vector driving expression of HA-tagged wild-
type TFIIB or the TFIIB S65A mutant derivative.
Forty-eight hours later, the cells were treated with 100 nM calyculin A where indicated for 30 min prior to lysis. Immunoprecipitation of the overexpressed
TFIIB was performed with anti-HA antibody in buffer containing phosphatase inhibitors. Immunoblots with anti-TFIIB, anti-Ssu72, or anti-CstF-64 antibodies
are shown. Below: the input lysates were immunoblotted with anti-HA antibody.
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data were quantitated and expressed as fold enrichment
over the signal generated by the amplification of a fragment
of the 18S gene (Figure 4A). Transfection of wild-type TFIIB
resulted in robust recruitment of both Ssu72 and CstF-64
to all three promoter and terminator regions. When TFIIB
S65A was overexpressed, the recruitment of both Ssu72 and
CstF-64 to the promoter was considerably impaired. At the
terminator, however, expression of TFIIB S65A significantly
reduced occupancy by CstF-64, but not Ssu72.
Both Ssu72 and CstF-64 can interact directly with TFIIB [7, 8,
15, 16]. We therefore prepared whole-cell lysates from 293T
cells and either mock incubated or incubated the extracts
with lambda phosphatase. Immunoprecipitation was per-
formed with anti-TFIIB, anti-Ssu72, anti-CstF-64, or control
IgG antibodies and immunoblotted with general anti-TFIIB
antibodies (Figure 4B, top). The anti-Ssu72 and anti-CstF-64
antibodies both coprecipitated TFIIB in the extracts that
were mock treated. However, in the extracts that had been
treated with lambda phosphatase, anti-Ssu72 antibodies
coprecipitated TFIIB but the anti-CstF-64 antibodies did not.
Immunoblotting with anti-TFIIB antibodies confirmed that
similar levels of TFIIB were present in the extracts (Figure 4B,
bottom). Thus, the interaction between Ssu72 and TFIIB is
phosphorylation independent, but the interaction between
TFIIB and CstF-64 is dependent on phosphorylation. Next,
we examined the effect of TFIIB serine 65 substitution with
alanine on the association of TFIIB with Ssu72 and CstF-64
by coimmunoprecipitation. 293T cells were transfected with
plasmids driving expression of either HA-tagged wild-type
TFIIB or HA-tagged TFIIB S65A. Whole-cell extracts were
prepared in the presence of phosphatase inhibitors from
untreated cells or cells that had been treated for 30 min with
the general serine/threonine phosphatase inhibitor calyculin A.
The ectopically expressed TFIIB was immunoprecipitated
with anti-HA antibodies, and the samples were immunoblottedwith anti-Ssu72, anti-CstF-64, or general anti-TFIIB antibodies
(Figure 4C). Although both wild-type TFIIB and the S65A deriv-
ative showed equivalent immunoprecipitation with general
anti-TFIIB antibodies, there was a significant reduction of
CstF-64 coimmunoprecipitation in the lysate containing TFIIB
S65A. Furthermore, the coimmunoprecipitation of CstF-64
with wild-type TFIIB was enhanced by calyculin A. In contrast,
the coimmunoprecipitation of Ssu72 with TFIIB was not
affected by S65A substitution or calyculin A. Taken together,
the data in Figure 4 show that recruitment of CstF-64 and
Ssu72 to the promoter is dependent upon TFIIB phosphoryla-
tion at residue serine 65, while the recruitment of CstF-64, but
not Ssu72, is specifically affected at the terminator. This is
due at least in part to the modulation of the TFIIB-CstF-64
interaction by phosphorylation of TFIIB serine 65. The data
also suggest that TFIIB-mediated recruitment of CstF to the
promoter and/or terminator is a prerequisite for the recruit-
ment of CPSF to the promoter, but not the terminator.
Purified DNA-PK can phosphorylate TFIIB serine 65 in vitro,
but there is no evidence as yet that DNA-PK is a physiologically
relevant TFIIB kinase [10]. Our attempts to purify the kinase
from the 0.5 M P11 fraction (see Figure 1) resulted in loss of
activity. However, the CDK inhibitor olomoucine was able to
inhibit the in vitro kinase reaction (Figure S3A). In addition,
the CDK inhibitor DRB at a 200 mM concentration (to which
the CDK7 activity of TFIIH is sensitive) inhibited phosphoryla-
tion of TFIIB serine 65 in vitro and in vivo (Figures S3B–S3E).
These data suggest that TFIIH might be the TFIIB serine 65
kinase. However, purified TFIIH failed to phosphorylate TFIIB
in vitro (data not shown), suggesting that other factors are
required.
Previous studies suggested that gene looping, which juxta-
poses promoters and terminators, is dependent on both TFIIB
and components of the CPSF and CstF complexes [8, 17–19].
Serine 65 is within a region of TFIIB termed the B finger or B
reader that is essential for these activities and also plays
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553a role in transcription start site selection, bubble formation,
and promoter clearance [1, 20–23]. Our current data show
that the phosphorylation of TFIIB serine 65 is required for the
efficient recruitment of CstF to the terminator and the recruit-
ment of both CPSF and CstF to the promoter at a stage
following phosphorylation of serine 5 of the pol II CTD, but
before the transition of pol II into a productive transcribing
enzyme. These observations suggest that phosphorylation of
TFIIB serine 65 is important for the formation of gene loops
and potentially forms a critical trigger for the initiation of tran-
scription. We also note that the TFIIB serine 65 derivatives do
not alter transcription start site selection (data not shown).
The TFIIB B finger/B reader plays a role in modulating the
conformation of TFIIB [1, 11, 24]. It is therefore possible that
phosphorylation of TFIIB serine 65 can alter the conformation
of TFIIB and its capacity to engage in contacts with other
components that are recruited to the PIC, for example CstF-64.
In this regard, it is noteworthy that transcriptional activators
can induce a conformational change in TFIIB, raising the
possibility that phosphorylation of TFIIB serine 65 also forms
part of the transcriptional activation process [1, 11, 24, 25].Supplemental Information
Supplemental Information includes three figures, Supplemental Experi-
mental Procedures, and one table and can be found with this article online
at doi:10.1016/j.cub.2010.01.052.
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